Membrane viability in the long-term peritoneal dialysis patient.
Schreiber
M J
MJ
Department of Nephrology and Hypertension, Cleveland Clinic Foundation, Ohio 44195, USA.
D001692:Biological Transport; D002196:Capillaries / Q000033:anatomy & histology / Q000187:drug effects / Q000502:physiology; D015314:Dialysis Solutions / Q000009:adverse effects; D004848:Epithelium / Q000033:anatomy & histology / Q000187:drug effects / Q000276:immunology; D005355:Fibrosis; D005947:Glucose / Q000009:adverse effects; D006025:Glycosaminoglycans / Q000378:metabolism; D006801:Humans; D008833:Microcirculation / Q000033:anatomy & histology / Q000187:drug effects / Q000502:physiology; D010343:Patient Admission; D010530:Peritoneal Dialysis / Q000009:adverse effects / Q000379:methods; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects / Q000379:methods; D010537:Peritoneum / Q000033:anatomy & histology / Q000098:blood supply / Q000187:drug effects / Q000276:immunology / Q000502:physiology*; D012307:Risk Factors; D014022:Tissue Survival; D016896:Treatment Outcome; D014462:Ultrafiltration
D015314:Dialysis Solutions; D006025:Glycosaminoglycans; D005947:Glucose